Medication info
Lozain Plus Tablets

Lozain Plus Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
CTC Bio, Inc.
Appearance
Pale yellow oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201508003 · Approved 2015.11.30 · Insurance code 669501800

Summary

Main use
Treatment of hypertension inadequately controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs at around 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Use of this medicine is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this medicine is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium for these patients, 25 mg, cannot be administered using this medicine.
Child dose
Under 18 years: There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
CTC Bio, Inc.

Efficacy & effects

Treatment of hypertension inadequately controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension who do not achieve adequate blood pressure control with monotherapy. It helps to manage blood pressure reliably and reduce the risk of cardiovascular complications.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs at around 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Use of this medicine is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this medicine is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium for these patients, 25 mg, cannot be administered using this medicine.

Child dose

Under 18 years: There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Patients with a known allergy to this medication or its components, severely impaired renal function, those undergoing dialysis, patients with severe liver disease, and women who are pregnant or may become pregnant should not take this medication. Patients with symptoms of hypotension or issues related to kidney or liver function, as well as those with diabetes or gout, should use this medication cautiously, and particular care is required for the elderly. As this medication lowers blood pressure, dizziness or drowsiness may occur at the beginning of treatment or when increasing the dose, necessitating caution while driving or operating machinery. Electrolyte levels in the blood should be monitored periodically during treatment, and caution is needed to prevent potassium levels from becoming too high or too low. During treatment, potassium supplements or salt substitutes containing potassium should not be taken without consulting a doctor. Due to the hydrochlorothiazide component, the skin may become sensitive to sunlight, so protection from UV rays is necessary, and any abnormal skin lesions should be reported to a doctor immediately. This medication may interact with other antihypertensive drugs or specific medications, so patients must inform their doctor or pharmacist of any other medications they are taking. Dehydration or electrolyte imbalance symptoms may occur during treatment, so if severe vomiting, diarrhea, or sweating occurs, a doctor should be consulted. This medication is not administered to children and adolescents as safety and efficacy have not been established. In case of overdose, hypotension or cardiac arrhythmias may occur, so immediate contact with a medical institution is necessary, and appropriate treatment should be administered if needed. This medication should be kept out of the reach of children and stored in its original container to maintain its quality.

Side effects

  • Skull formation deficiency
  • anuria
  • low blood pressure
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 132 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • skin peeling phenomenon
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • low blood pressure
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neurological irritability
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disturbances
  • drowsiness
  • tremors
  • dizziness
  • shortness of breath
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste abnormalities
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequent urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • hemolytic anemia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • hyperuricemia
  • muscle spasms
  • anxiety
  • renal failure
  • impaired renal function
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • Stevens-Johnson syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal exudate
  • angioedema
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in an opaque container. It is recommended to store it at room temperature, between 1°C and 30°C.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.